Drug Index



Mechanism :

Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing relaxation of vascular smooth muscle, resulting in coronary vasodilation and reduced blood pressure.

Indication :

• Hypertension

Contraindications :

Hypersensitivity to isradipine or any component of the formulation.

Dosing :

Off-label use:

Oral: Initial: 0.15-0.2 mg/kg/day in 3-4 divided doses; maximum 0.8 mg/kg/day, up to 20 mg daily.

Adverse Effect :

Headache, edema, flushing, tachycardia, palpitations, dizziness, skin rash, nausea, abdominal pain, diarrhea, weakness, urinary frequency, dyspnea.

Interaction :

Ondansetron: Isradipine and ondansetron both increase QTc interval.
Mefloquine: Mefloquine increases toxicity of isradipine by QTc interval.
CYP3A4 Inducers: May increase the metabolism of CYP3A4 Substrates.
CYP3A4 Inhibitors: May decrease the metabolism of CYP3A4 Substrates.
Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa.

03/03/2020 19:21:15 Isradipine
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0